CD274 and non-small cell lung carcinoma: However, anlotinib combined with a bispecific anti-PD-1 and anti-CTLA-4 antibody did not provoke grade 4 or 5 toxicity among 18 first-line PD-L1 positive NSCLC patients, including nine with squamous histology.